Asset Details
Do you wish to reserve the book?
HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure
Do you wish to request the book?
HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure
2017
Overview
The success of many current vaccines relies on a formulation that incorporates an immune activating adjuvant. This will hold true for the design of a successful therapeutic HIV vaccine targeted at controlling reactivated virus following cessation of combined antiretroviral therapy (cART). The HIV accessory protein Nef functions by interfering with HIV antigen presentation through the major histocompatibility complex I (MHC-I) pathway thereby suppressing CD8
+
cytotoxic T cell (CTL)-mediated killing of HIV infected cells. Thus, this important impediment to HIV vaccine success must be circumvented. This review covers our current knowledge of Nef inhibitors that may serve as immune adjuvants that will specifically restore and enhance CTL-mediated killing of reactivated HIV infected cells as part of an overall vaccine strategy to affect a cure for HIV infection.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
Acquired immune deficiency syndrome
/ AIDS
/ Animals
/ HIV
/ HIV Infections - drug therapy
/ HIV vaccine development in Canada
/ HIV-1
/ Human immunodeficiency virus
/ Humans
/ Kinases
/ Latency
/ Major histocompatibility complex
/ Medicine
/ Mice
/ Nef
/ nef Gene Products, Human Immunodeficiency Virus - antagonists & inhibitors
/ nef Gene Products, Human Immunodeficiency Virus - genetics
/ nef Gene Products, Human Immunodeficiency Virus - immunology
/ Proteins
/ Review
/ Rodents
/ T-Lymphocytes, Cytotoxic - immunology
/ Vaccines
/ Virology
/ Viruses
